Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes.
Victor M LuKrishnan RavindranChristopher S GraffeoAvital PerryJamie J Van GompelDavid J DanielsMichael J LinkPublished in: Journal of neuro-oncology (2019)
Bevacizumab may arrest both tumor progression and hearing loss in select NF2 patients presenting with VS lesions. However, a considerable proportion of patients are anticipated to experience serious adverse events; correspondingly, judicious use of bevacizumab for symptomatic management of VS in NF2 is recommended.
Keyphrases
- hearing loss
- end stage renal disease
- metastatic colorectal cancer
- signaling pathway
- lps induced
- chronic kidney disease
- ejection fraction
- newly diagnosed
- oxidative stress
- peritoneal dialysis
- pi k akt
- nuclear factor
- poor prognosis
- inflammatory response
- cell cycle
- patient reported outcomes
- immune response
- toll like receptor